Docs concerned for the use of Favipiravir for COVID in India
By MYBRANDBOOK
Favipiravir, an antiviral drug for the treatment of mild-to-moderate COVID-19 cases, was launched recently by Glenmark Pharmaceuticals. According to reports, the drug has been launched after it received approval from the Drug Controller General of India to manufacture and market the medicine.
The antiviral drug Favipiravir has been approved in Japan since 2014 for the treatment of novel or re-emerging influenza virus infections. It works by inhibiting viral replication and reducing the viral load in a patient. It is an experimental medicine being repurposed for COVID-19.
According to Glenn Saldanha, Chairman and Managing Director of Glenmark Pharmaceuticals the approval has come at a time when cases in India are spiralling, putting tremendous pressure on our healthcare system.
The drug FabiFlu will be available as a prescription-based medication for Rs 103 per tablet, with the recommended dose being 1800 mg twice daily on day 1, followed by 800 mg twice daily up to day 14.
The drug is not recommended in patients with severe renal, hepatic impairment, and in pregnant and lactating women.
Glenmark has claimed that Favipiravir shows clinical improvements of up to 88% in COVID-19 disease, with a rapid reduction in viral load by 4 days.
Favipiravir is being studied in at least 18 trials around the world as a potential treatment for COVID-19. Earlier last month, Glenmark also announced that it is conducting another clinical trial to evaluate the efficacy of two antivirals Favipiravir and Umifenovir as a combination therapy in moderate hospitalized adult COVID-19 patients in India.
But according to doctors there is insufficient evidence in favour of the medicine. A large portion of doctors don’t feel there is any real requirement of the medicine for mild attacks. They feel there is so much panic and fear around the disease that they will be forced to arrange for the medicine even if they have no funds - when in reality, a mild COVID case may recover either without medication, or with medicines costing no more than Rs 10.
BHIM to join e-commerce, competing with PhonePe and Google Pay
The government-supported payment software BHIM is getting ready to join t...
The latest version of X helps prevent deepfakes on social medi
To combat deepfakes and shallowfakes, Elon Musk revealed a new update t...
India and Namibia collaborate on a payment system similar to U
Once operational, the platform will enable digital transactions in Namibia,...
Sebi issues show-cause notices to six Adani group firms
Sebi issued show-cause notices to six Adani Group firms, including Adani ...
TEJAS NETWORKS INDIA PVT. LTD.
TP-LINK INDIA PVT LTD.
TVS ELECTRONICS LTD.
LUMINOUS POWER TECHNOLOGIES PVT. LTD.
Technology Icons Of India 2023: Rajiv Memani
As Chair of the EY Global Emerging Markets Committee, Rajiv connects e...
Technology Icons Of India 2023: Lt Gen (Dr.) Rajesh Pant (Retd.)
LT Gen(Dr.) Rajesh Panth (Retd.), National cyber security coordination...
Technology Icons Of India 2023: Lt Gen (Dr.) Rajesh Pant (Retd.)
LT Gen(Dr.) Rajesh Panth (Retd.), National cyber security coordination...
Aadhaar: Architecting the World's Largest Biometric Identity System
The Unique Identification Authority of India (UIDAI) is a statutory au...
HPCL is transforming the energy landscape, across the nation and beyond
HPCL is world-class energy company known for caring and delighting the...
NIC bridging the digital divide and supporting government in eGovernance
The National Informatics Centre (NIC) is an Indian government departme...
EXCLUSIVE NETWORKS SALES INDIA PVT. LTD.
Exclusive Networks is a globally trusted cybersecurity specialist hel...
TECHNOBIND SOLUTIONS PVT. LTD.
TechnoBind’s business model is focused on identifying and partnering...
SAVEX TECHNOLOGIES PVT. LTD.
Savex Technologies is the 3rd largest Information & Communication Tec...